Thursday, 15 October 2026European Markets

ABG SUNDAL COLLIER And BOURSE DIRECT Have A High Dividend Yield And Return On Equity In The Capital Markets Industry.

Loading stream...

(vianews) - abg sundal collier (abg.ol) is among this list of stock assets with the highest dividend rate and return on equity on the capital markets industry.

financial asset price forward dividend yield return on equity
abg sundal collier (abg.ol) kr5.09 9.65% 24.73%
bourse direct (bsd.pa) €5.46 1.46% 14.89%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. abg sundal collier (abg.ol)

9.65% forward dividend yield and 24.73% return on equity

abg sundal collier holding asa, together with its subsidiaries, provides investment banking, stockbroking, and corporate advisory services in norway, sweden, denmark, and internationally. the company offers corporate financing services for corporate clients to raise capital through equity or debt financing. it is also involved in advising companies in relation to mergers, acquisitions, and sales, as well as to various real asset transactions and other advisory services. in addition, the company provides secondary security brokerage and research services. the company was founded in 1984 and is headquartered in oslo, norway.

earnings per share

as for profitability, abg sundal collier has a trailing twelve months eps of kr0.41.

pe ratio

abg sundal collier has a trailing twelve months price to earnings ratio of 12.41. meaning, the purchaser of the share is investing kr12.41 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.73%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, abg sundal collier's stock is considered to be overbought (>=80).

volume

today's last reported volume for abg sundal collier is 75852 which is 75.47% below its average volume of 309266.

earnings before interest, taxes, depreciation, and amortization

abg sundal collier's ebitda is 1.31.

more news about abg sundal collier.

2. bourse direct (bsd.pa)

1.46% forward dividend yield and 14.89% return on equity

bourse direct sa provides internet stock brokerage services in france. it offers a platform of services, tools, and financial products, including french and foreign equities, derivatives, trackers, warrants, certificates, turbos, mutual funds, ucits, and cfds, as well as tax exemption, retirement, real estate, and life insurance products through the boursedirect.fr, capitol.fr, tradebox.fr, abssysteme.fr, wargny.com, and mesactions.com sites. the company was founded in 1996 and is headquartered in paris, france. bourse direct sa is a subsidiary of e-viel sa.

earnings per share

as for profitability, bourse direct has a trailing twelve months eps of €0.1.

pe ratio

bourse direct has a trailing twelve months price to earnings ratio of 54.6. meaning, the purchaser of the share is investing €54.6 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.89%.

volatility

bourse direct's last week, last month's, and last quarter's current intraday variation average was 1.68%, 0.20%, and 1.81%.

bourse direct's highest amplitude of average volatility was 1.68% (last week), 2.70% (last month), and 1.81% (last quarter).

moving average

bourse direct's value is under its 50-day moving average of €5.48 and way above its 200-day moving average of €4.52.

more news about bourse direct.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com